Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Ning

Showing results (981-990 of 997) with videos related to

Pageof 100
Sort By:
Current Oncology (Toronto, Ont.)|August 28, 2024
Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT ExperienceAbhishek A Solanki, Kevin Zheng, Alicia N Skipworth, et al.
Surgical Endoscopy|December 1, 2020
Evaluating the advantages of treating acute cholecystitis by following the Tokyo Guidelines 2018 (TG18): a study emphasizing clinical outcomes and medical expendituresYu-Ning Lin, Yu-Tung Wu, Chih-Yuan Fu, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
Biomedical and Environmental Sciences : BES|August 9, 2022
The Influence of Diabetes, Hypertension, and Hyperlipidemia on the Onset of Age-Related Macular Degeneration in North China: The Kailuan Eye StudyYong Peng Zhang, Ya Xing Wang, Jin Qiong Zhou, et al.
European Urology|August 5, 2015
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerElizabeth R Plimack, Roland L Dunbrack, Timothy A Brennan, et al.
Nature Genetics|November 5, 2013
Activating ESR1 mutations in hormone-resistant metastatic breast cancerDan R Robinson, Yi-Mi Wu, Pankaj Vats, et al.
Immunity|December 9, 2025
A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal liver pathology in neonatesYanhui Xu, Xixi Chen, Rongli Fang, et al.
Chinese Journal of Integrative Medicine|November 24, 2018
Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up StudyYing Zheng, Nian-Song Wang, Yu-Ning Liu, et al.
JAMA Oncology|February 25, 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsErin F Cobain, Yi-Mi Wu, Pankaj Vats, et al.
Chinese Medical Journal|October 21, 2017
Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical StudyYing Zheng, Guang-Yan Cai, Li-Qun He, et al.
Pageof 100

Showing results (981-990 of 997) with videos related to

Sort By:
Pageof 100
Current Oncology (Toronto, Ont.)|August 28, 2024
Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT ExperienceAbhishek A Solanki, Kevin Zheng, Alicia N Skipworth, et al.
Surgical Endoscopy|December 1, 2020
Evaluating the advantages of treating acute cholecystitis by following the Tokyo Guidelines 2018 (TG18): a study emphasizing clinical outcomes and medical expendituresYu-Ning Lin, Yu-Tung Wu, Chih-Yuan Fu, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
Biomedical and Environmental Sciences : BES|August 9, 2022
The Influence of Diabetes, Hypertension, and Hyperlipidemia on the Onset of Age-Related Macular Degeneration in North China: The Kailuan Eye StudyYong Peng Zhang, Ya Xing Wang, Jin Qiong Zhou, et al.
European Urology|August 5, 2015
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerElizabeth R Plimack, Roland L Dunbrack, Timothy A Brennan, et al.
Nature Genetics|November 5, 2013
Activating ESR1 mutations in hormone-resistant metastatic breast cancerDan R Robinson, Yi-Mi Wu, Pankaj Vats, et al.
Immunity|December 9, 2025
A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal liver pathology in neonatesYanhui Xu, Xixi Chen, Rongli Fang, et al.
Chinese Journal of Integrative Medicine|November 24, 2018
Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up StudyYing Zheng, Nian-Song Wang, Yu-Ning Liu, et al.
JAMA Oncology|February 25, 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsErin F Cobain, Yi-Mi Wu, Pankaj Vats, et al.
Chinese Medical Journal|October 21, 2017
Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical StudyYing Zheng, Guang-Yan Cai, Li-Qun He, et al.
Pageof 100